Cargando…
The Pleiotropic Effects of Sodium–Glucose Cotransporter-2 Inhibitors: Beyond the Glycemic Benefit
ABSTRACT: Type 2 diabetes (T2D) is associated with an increased risk of macro- and microvascular complications, including cardiovascular disease (CVD), heart failure (HF), and chronic kidney disease (CKD). Of the currently available glucose-lowering therapies, sodium–glucose cotransporter-2 inhibito...
Autores principales: | Patel, Dhiren K., Strong, Jodi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6778563/ https://www.ncbi.nlm.nih.gov/pubmed/31456166 http://dx.doi.org/10.1007/s13300-019-00686-z |
Ejemplares similares
-
Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors: Renoprotective Mechanisms beyond Glycemic Control
por: Takata, Tomoaki, et al.
Publicado: (2021) -
Pleiotropic effect of sodium-glucose cotransporter 2 inhibitors on blood pressure
por: Kao, Ting-Wei, et al.
Publicado: (2022) -
Sodium-glucose Cotransporter-2 Inhibitors: Moving Beyond the Glycemic Treatment Goal
por: Gupta, Vishal, et al.
Publicado: (2017) -
Pleiotropic Benefits of DPP-4 Inhibitors Beyond Glycemic Control
por: Kang, Seon Mee, et al.
Publicado: (2021) -
Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors in Cardiovascular Disease and Chronic Kidney Disease
por: Rastogi, Anjay, et al.
Publicado: (2023)